Global Injectable Drug Delivery Devices Market 2024–2033

Reports Description

As per the current market research conducted by the CMI Team, the global Injectable Drug Delivery Devices Market is expected to record a CAGR of 10.21% from 2024 to 2033. In 2024, the market size is projected to reach a valuation of USD 17,032.08 Million. By 2033, the valuation is anticipated to reach USD 40,956.3 Million.

Number of Death of Cardiovascular Disease

Source: Our World in Data

Injectable drug delivery devices are medical tools designed to deliver medications directly into a patient’s body through various types of injections. These devices are essential for administering drugs that cannot be taken orally, ensuring precise dosage, rapid onset of action, and targeted delivery.

Injectable devices deliver medications directly into the bloodstream or tissues, allowing for a quicker therapeutic response compared to oral or transdermal routes. This is particularly beneficial in emergencies where immediate drug action is required, such as in anaphylactic shock or cardiac arrest.

Injectable Drug Delivery Devices Market – Significant Growth Factors

The Injectable Drug Delivery Devices Market presents significant growth opportunities due to several factors:

• Rising prevalence of chronic diseases: The increasing prevalence of chronic diseases is a primary factor driving the growth of the injectable drug delivery devices market. Chronic conditions such as diabetes, rheumatoid arthritis, and cardiovascular diseases are on the rise globally, necessitating long-term and regular injectable therapies. The growing use of biological drugs, which require injection due to their complex molecular structures, further fuels this demand.

• Growing in the number of aging populations across the globe: Demographic shifts, particularly the aging global population, significantly contribute to the growth of the injectable drug delivery devices market. Older adults are more susceptible to chronic diseases and often require ongoing medical interventions, including injectable therapies. As the proportion of elderly individuals increases, so does the demand for medications that can be administered through injectables.

• Growth in biopharmaceutical industry: Biopharmaceuticals, or biologics, are complex drugs derived from living cells and are increasingly used to treat a variety of conditions, including autoimmune diseases, cancers, and rare genetic disorders. Due to their large molecular size and complexity, these drugs often require injectable delivery to ensure they reach their target sites in the body effectively. As the biopharmaceutical industry expands, with many new biologics in development and gaining regulatory approval, the demand for compatible and sophisticated injectable devices rises correspondingly.

• Increasing expansion of therapeutic indications: Injectable drugs are increasingly being used to treat a broader range of conditions, including hormonal imbalances, neurological disorders, and infectious diseases. This broadening of therapeutic applications increases the demand for specialized injectable devices that cater to various medical needs. As new therapeutic areas continue to emerge, the injectable drug delivery devices market is poised for sustained growth, driven by the need for versatile and effective delivery systems.

• Enhancing patient centricity and compliance with sterile injectables: Modern injectable devices are increasingly designed with the patient in mind, featuring user-friendly interfaces, ergonomic designs, and pre-filled syringes that simplify the administration process. These features make self-administration more straightforward and less intimidating, reducing the complexity of injections and encouraging proper usage.

Injectable Drug Delivery Devices Market – Mergers and Acquisitions

The Injectable Drug Delivery Devices Market has seen several mergers and acquisitions in recent years, with companies seeking to expand their market presence and leverage synergies to improve their product offerings and profitability. Some notable examples of mergers and acquisitions in the Injectable Drug Delivery Devices Market include:

• In April 2024, Eli Lilly and Nexus Pharmaceuticals agreed to acquire a manufacturing facility in Pleasant Prairie, Wisconsin, to enhance their global network for manufacturing parenteral products and meet the growing demand for their medicines. The FDA-approved facility is expected to begin production by the end of 2025.

• In April 2024, Gerresheimer partnered with US digital health company RxCap, acquiring a minority stake. Gerresheimer’s subsidiary Centor will gain exclusive distribution rights for RxCap’s adherence solutions, including connected prescription vial closure devices and cloud-based software.

• In February 2022, Antares Pharma, with over 30 years of experience in drug device engineering, specializes in custom-designed drug delivery devices for individual patients. Their approach emphasizes personalized solutions, empowering patients to self-administer therapies. They have received FDA approvals for seven drug-device combination products, including their proprietary XYOSTED® and EpiPen® products. Their commitment to innovation and patient-centric design drives continuous advancements in the injectable drug delivery devices market.

These mergers and acquisitions helped companies expand their product offerings, improve their market presence, and capitalize on growth opportunities in the injectable drug delivery devices market. The trend is expected to continue as companies seek to gain a competitive edge in the market.

COMPARATIVE ANALYSIS OF THE RELATED MARKET

Injectable Drug Delivery Devices Market – Significant Threats

The injectable drug delivery devices market faces several significant threats that could impact its growth and profitability in the future. Some of these threats include:

• High cost of injectable drug delivery devices: Advanced injectables, such as auto-injectors and wearable injectors, often come with a significant price tag due to the sophisticated technology and materials used in their manufacture. This high cost can limit accessibility, especially in low- and middle-income countries where healthcare budgets are constrained.

• High risk of needle-related complications: The risk of needle-related complications, such as needlestick injuries and infections, can also restrain market growth. Needlestick injuries are a concern for both healthcare providers and patients, leading to potential exposure to bloodborne pathogens. These risks necessitate stringent safety measures and training, which can increase the overall cost and complexity of using injectable devices.

• Increasing use of alternative drug delivery method: Advances in pharmaceutical technology and a better understanding of drug pharmacokinetics and patient preferences have led to the development and adoption of various non-injectable drug delivery methods. These alternatives, which include oral, transdermal, and inhalation routes, offer several advantages that appeal to both patients and healthcare providers, thereby limiting the demand for injectable devices.

• Technological challenges associated with injectable drug delivery devices: Technological challenges in the development and manufacturing of injectable drug delivery devices can impede market growth. Developing devices that are both technologically advanced and user-friendly is a complex task that requires significant investment in research and development.

• Stringent government regulations for the medical waste disposal: Environmental concerns related to the disposal of injectable devices and needles can also act as a restraint. The proper disposal of sharps and single-use injectables is crucial to prevent environmental contamination and public health risks.

Category-Wise Insights:

By Device Type

• Conventional Drug Delivery Devices: Conventional drug delivery devices represent the traditional methods used for administering injectable medications. These devices have been in use for decades and are well-established in clinical practice. Conventional injectable devices include syringes and needles, vials and ampoules, and infusion pumps.

• Advanced Drug Delivery Devices: Advanced drug delivery devices are systems designed to provide therapeutic concentrations of drugs to target sites in the body over prolonged periods of time. These devices aim to overcome the limitations of conventional dosage forms, such as fluctuating drug levels and the need for frequent dosing, by controlling the temporal delivery of drugs.

• Prefilled Syringes: Prefilled syringes are ready-to-use injection devices prefilled with a specific dose of medication. They eliminate the need for manual filling of syringes by healthcare providers, reducing the risk of dosing errors and contamination. Prefilled syringes offer convenience, accuracy, and sterility, making them ideal for self-administration by patients and healthcare professionals alike.

• Injectable Pens: Injectable pens or pen injectors, also known as insulin pens or pen injectors, are reusable devices used for the injection of insulin and other injectable medications. They resemble a pen in shape and size, with a cartridge containing the medication and a dial for adjusting the dosage. Pen injectors offer convenience, portability, and precise dosing, making them popular among patients with diabetes and other chronic conditions requiring frequent injections.

• Auto Injectors: Auto-injectors are self-contained devices designed to automatically inject a pre-measured dose of medication into the patient’s body. They are commonly used for the self-administration of medications, such as epinephrine for allergic reactions or biologic drugs for chronic conditions like rheumatoid arthritis. Auto-injectors are user-friendly and typically feature a spring-loaded mechanism for needle insertion and drug delivery.

• Needle-free Injectors: Needle-free injectors, also known as jet injectors, use a high-pressure stream of medication to penetrate the skin and deliver the drug subcutaneously or intramuscularly. They eliminate the need for needles, reducing the risk of needlestick injuries and providing a painless alternative for patients who fear needles. Needle-free injectors are particularly useful for delivering vaccines and other medications requiring rapid administration.

• Others: Other types of advanced drug delivery devices include wearable injectors, smart injectors, and patch pumps. Wearable injectors are worn on the body and deliver large volumes of medication over extended periods. Smart injectors incorporate digital technology for enhanced drug delivery and patient monitoring. Patch pumps are adhesive patches that deliver medication through the skin, providing continuous or on-demand dosing for conditions such as pain management and hormone therapy.

By Therapeutic Application

• Cardiovascular Disease: Injectable drug delivery devices are widely used in the treatment of cardiovascular diseases, including hypertension, heart failure, and thrombotic disorders. Medications such as anticoagulants, antiplatelet agents, and vasodilators are often administered via injectable devices to manage these conditions. Injectable devices allow for precise dosing and rapid onset of action, making them ideal for emergencies such as myocardial infarction or stroke. Additionally, long-acting injectable formulations provide sustained release of medications, improving patient adherence and reducing the risk of cardiovascular events.

• Autoimmune Disorders: Autoimmune disorders, such as rheumatoid arthritis, multiple sclerosis, and inflammatory bowel disease, require long-term treatment with immunosuppressive medications to manage symptoms and prevent disease progression. Injectable drug delivery devices, including prefilled syringes, auto-injectors, and wearable injectors, offer convenient and reliable options for administering biologic drugs and disease-modifying antirheumatic drugs (DMARDs). These devices allow patients to self-administer their medications at home, reducing the need for frequent clinic visits and improving treatment adherence.

• Diabetes: Diabetes is a chronic metabolic disorder characterized by high blood sugar levels, which can lead to serious complications such as cardiovascular disease, kidney failure, and blindness. Injectable drug delivery devices, such as insulin pens and insulin pumps, are essential for managing diabetes by delivering insulin to regulate blood sugar levels. These devices offer precise dosing, ease of use, and flexibility in insulin administration, allowing patients to customize their treatment regimens according to their lifestyle and dietary habits. The demand for injectable diabetes devices is increasing globally due to the rising prevalence of diabetes and the growing adoption of insulin therapy.

• Oncology: Oncology is another therapeutic area where injectable drug delivery devices play a critical role in cancer treatment. Chemotherapy drugs, monoclonal antibodies, and targeted therapies are often administered via injectable devices to deliver medications directly to cancer cells while minimizing systemic toxicity. Injectable devices such as infusion pumps, prefilled syringes, and implantable ports enable precise dosing, continuous infusion, and targeted delivery of anticancer drugs, improving treatment efficacy and reducing side effects. The demand for injectable oncology devices is driven by the growing incidence of cancer worldwide and the increasing use of injectable therapies in cancer treatment protocols.

• Others: In addition to the aforementioned therapeutic areas, injectable drug delivery devices are used in a wide range of other medical specialties, including neurology, gastroenterology, dermatology, and pain management. Neurological disorders such as multiple sclerosis, Parkinson’s disease, and migraine headaches often require injectable medications for symptom management and disease modification. Gastrointestinal disorders such as Crohn’s disease and ulcerative colitis may be treated with injectable biologic drugs to reduce inflammation and control symptoms. Injectable devices are also used in dermatology for administering botulinum toxin injections for cosmetic and therapeutic purposes and in pain management for delivering analgesic medications to relieve chronic pain.

By Distribution Channel

• Hospital Pharmacies: Hospital pharmacies are a key distribution channel for injectable drug delivery devices, especially for medications administered in clinical settings or during hospital stays. These pharmacies stock a wide range of injectable devices, including prefilled syringes, infusion pumps, and auto-injectors, to meet the needs of inpatient and outpatient care.

• Retail Pharmacies & Drug Stores: Retail pharmacies and drug stores serve as important distribution channels for injectable drug delivery devices, particularly for medications prescribed for chronic conditions that require long-term treatment. Retail pharmacists provide counseling and support to patients, ensuring they understand how to use their injectable devices safely and effectively.

• Online Pharmacies: Online pharmacies have emerged as a popular distribution channel for injectable drug delivery devices, providing patients with the convenience of ordering medications and devices from the comfort of their homes. Online pharmacies offer a wide selection of injectable devices and medications, often at competitive prices, and provide fast and discreet delivery to customers’ doorsteps. Patients can access a range of injectable devices, including prefilled syringes, auto-injectors, and insulin pens, from reputable online pharmacies, with the added convenience of access to educational resources and support services.

• Others: Other distribution channels for injectable drug delivery devices may include specialty pharmacies, home healthcare providers, and direct-to-consumer sales channels. Specialty pharmacies focus on providing medications and devices for complex medical conditions, including injectable therapies for oncology, autoimmune disorders, and specialty biologics. Home healthcare providers offer delivery and administration services for injectable medications, allowing patients to receive treatment in the comfort of their homes.

Report Scope

Injectable Drug Delivery Devices Market – Regional Analysis

The Injectable Drug Delivery Devices Market is segmented into various regions, including North America, Europe, Asia-Pacific, and LAMEA. Here is a brief overview of each region:

• North America: North America holds a significant share of the global injectable drug delivery devices market, driven by factors such as advanced healthcare infrastructure, high prevalence of chronic diseases, and technological advancements. The region is home to several key market players and research institutions focusing on drug delivery technologies. Increasing adoption of biological therapies and specialty medications, coupled with rising healthcare expenditure, contributes to market growth.

• Europe: Europe is another prominent region in the global injectable drug delivery devices market, characterized by a strong pharmaceutical industry, robust healthcare infrastructure, and supportive regulatory environment. The region has a high prevalence of chronic diseases, driving the demand for injectable therapies and devices. Technological innovations in drug delivery systems, along with increasing investments in research and development, propel market growth.

• Asia-Pacific: Asia Pacific is emerging as a rapidly growing market for injectable drug delivery devices, fuelled by factors such as increasing healthcare spending, rising prevalence of chronic diseases, and expanding access to healthcare services. The region has a large and aging population, driving demand for injectable therapies to manage chronic conditions such as diabetes, cardiovascular diseases, and cancer. Technological advancements and growing awareness about the benefits of injectable devices contribute to market growth.

• LAMEA (Latin America, Middle East, and Africa): The LAMEA region represents a growing market for injectable drug delivery devices, driven by factors such as increasing healthcare expenditure, rising prevalence of chronic diseases, and improving access to healthcare services. The region has a diverse healthcare landscape, with varying levels of infrastructure and healthcare delivery systems across countries. Growing investments in healthcare infrastructure and government initiatives to improve healthcare access drive market growth.

Competitive Landscape – Injectable Drug Delivery Devices Market

The injectable drug delivery devices market is highly competitive, with a large number of manufacturers and retailers operating globally. Some of the key players in the market include:

• Antares Pharma
• AbbVie Inc.
• Baxter International Inc.
• Becton Dickinson and Company
• Biocon
• Eli Lilly and Company
• Gerresheimer AG
• Johnson & Johnson
• Novartis AG
• Novo Nordisk A/S
• Pfizer Inc.
• Schott AG
• Terumo Corporation
• Teva Pharmaceutical Industries Ltd.
• West Pharmaceutical Services Inc.
• Others

These companies operate in the market through various strategies such as product innovation, mergers and acquisitions, and partnerships.

New players entering the injectable drug delivery devices market are adopting strategies such as differentiating their product from the other key market players with, a high focus on the therapeutic areas along with other market penetration and pricing strategies.

New market players often differentiate themselves by introducing innovative injectable delivery devices that offer unique features or address unmet needs in the market. Moreover, targeting niche markets allows new players to tailor their products and services to meet the unique needs of patients and healthcare providers, thereby gaining a competitive advantage in the market.

The Injectable Drug Delivery Devices Market is segmented as follows:

By Device Type

• Conventional Drug Delivery Devices
• Advanced Drug Delivery Devices
  • Prefilled Syringes
  • Injectable Pens
  • Auto Injectors
  • Needle-free Injectors
  • Others

By Therapeutic Application

• Cardiovascular Disease
• Autoimmune Disorders
• Diabetes
• Oncology
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies & Drug Stores
• Online Pharmacies
• Others

Regional Coverage:

North America

• U.S.
• Canada
• Mexico
• Rest of North America

Europe

• Germany
• France
• U.K.
• Russia
• Italy
• Spain
• Netherlands
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• New Zealand
• Australia
• South Korea
• Taiwan
• Rest of Asia Pacific

The Middle East & Africa

• Saudi Arabia
• UAE
• Egypt
• Kuwait
• South Africa
• Rest of the Middle East & Africa

Latin America

• Brazil
• Argentina
• Rest of Latin America